Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Quality initiative in first-line multiple myeloma assessing the use of anti-CD38 agents and quadruplet therapy

Joseph Franz, Dhaval Mehta, Kathleen Dorritie, Rushir Choksi, Taya Salman, Mike Gart, Lisa Kunst, Harshal Dave, Kristen Henn, Prashanth Jain, Brandon Wang, Prateesh Varughese, Lisa Morere, Jeffrey Scott, Paul Richardson

Blood (2025) 146 (Supplement 1): 8120.

https://doi.org/10.1182/blood-2025-8120

Published: 2025

Journal Articles

Factors impacting treatment choice with a CD38 antibody, immunomodulator, proteasome inhibitor, and dexamethasone in first line multiple myeloma patients: A real-world US study

Joseph Franz, Joseph Mikhael, Dhaval Mehta, Rushir Choksi, Taya Salman, Mike Gart, John Li, Harshal Dave, Lisa Kunst, Kristen Henn, Prashanth Jain, Brandon Wang, Prateesh Varughese, Lisa Morere, Jeffrey Scott, Paul Richardson

Blood (2025) 146 (Supplement 1): 3988.

https://doi.org/10.1182/blood-2025-3988

Published: 2025

Journal Articles

Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia

Kenneth A. Foon, Dhaval Mehta, Suzanne Lentzsch, Patricia Kropf, Stanley Marks, Diana Lenzner, Louis Pietragallo, Mathew Sulecki, Ahmad Tarhini, Michael Boyiadzis

Blood (2012) 119 (13): 3184–3185.

https://doi.org/10.1182/blood-2012-01-408047

Published: 2012

Journal Articles

A Combination of Rituxan, Cyclophosphamide and Dexamethasone (RCD) Results in Long-Lasting Responses in Autoimmune Anemia and Thrombocytopenia in CLL Patients: A Single Institution Study.

Matthew S. Kaufman, MD, Yehuda Z. Lebowicz, MD, Nancy Driscoll, RPA-C, Christina Johnson, RPA-C, Dale Janson, RPA-C, Angelica Caramanica, RPA-C, Rajasree Roy, MD, Neetu Radhakrishnan, MD, Dhaval Mehta, MD, Mark Hoffman, MD, Dilip Patel, MD, Nina Kohn, MBA,MA, Kanti R. Rai, MD

Blood (2006) 108 (11): 2832.

https://doi.org/10.1182/blood.V108.11.2832.2832

Published: 2006

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Quality initiative in first-line multiple myeloma assessing the use of anti-CD38 agents and quadruplet therapy

Factors impacting treatment choice with a CD38 antibody, immunomodulator, proteasome inhibitor, and dexamethasone in first line multiple myeloma patients: A real-world US study

Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia

A Combination of Rituxan, Cyclophosphamide and Dexamethasone (RCD) Results in Long-Lasting Responses in Autoimmune Anemia and Thrombocytopenia in CLL Patients: A Single Institution Study.

Email alerts

ASH Publications

American Society of Hematology

Update search

Quality initiative in first-line multiple myeloma assessing the use of anti-CD38 agents and quadruplet therapy

Factors impacting treatment choice with a CD38 antibody, immunomodulator, proteasome inhibitor, and dexamethasone in first line multiple myeloma patients: A real-world US study

Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia

A Combination of Rituxan, Cyclophosphamide and Dexamethasone (RCD) Results in Long-Lasting Responses in Autoimmune Anemia and Thrombocytopenia in CLL Patients: A Single Institution Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only